Supernus Pharmaceuticals Gross Profit 2011-2024 | SUPN
Supernus Pharmaceuticals gross profit from 2011 to 2024. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Supernus Pharmaceuticals Annual Gross Profit
(Millions of US $) |
| 2023 |
$524 |
| 2022 |
$580 |
| 2021 |
$505 |
| 2020 |
$468 |
| 2019 |
$376 |
| 2018 |
$394 |
| 2017 |
$287 |
| 2016 |
$203 |
| 2015 |
$139 |
| 2014 |
$87 |
| 2013 |
$11 |
| 2012 |
$1 |
| 2011 |
$1 |
| 2010 |
$0 |
Supernus Pharmaceuticals Quarterly Gross Profit
(Millions of US $) |
| 2024-06-30 |
$150 |
| 2024-03-31 |
$127 |
| 2023-12-31 |
$145 |
| 2023-09-30 |
$134 |
| 2023-06-30 |
$114 |
| 2023-03-31 |
$130 |
| 2022-12-31 |
$144 |
| 2022-09-30 |
$151 |
| 2022-06-30 |
$150 |
| 2022-03-31 |
$135 |
| 2021-12-31 |
$142 |
| 2021-09-30 |
$130 |
| 2021-06-30 |
$116 |
| 2021-03-31 |
$116 |
| 2020-12-31 |
$125 |
| 2020-09-30 |
$134 |
| 2020-06-30 |
$118 |
| 2020-03-31 |
$91 |
| 2019-12-31 |
$96 |
| 2019-09-30 |
$97 |
| 2019-06-30 |
$101 |
| 2019-03-31 |
$82 |
| 2018-12-31 |
$112 |
| 2018-09-30 |
$99 |
| 2018-06-30 |
$96 |
| 2018-03-31 |
$87 |
| 2017-12-31 |
$84 |
| 2017-09-30 |
$76 |
| 2017-06-30 |
$72 |
| 2017-03-31 |
$55 |
| 2016-12-31 |
$59 |
| 2016-09-30 |
$53 |
| 2016-06-30 |
$49 |
| 2016-03-31 |
$42 |
| 2015-12-31 |
$41 |
| 2015-09-30 |
$37 |
| 2015-06-30 |
$34 |
| 2015-03-31 |
$27 |
| 2014-12-31 |
$29 |
| 2014-09-30 |
$21 |
| 2014-06-30 |
$28 |
| 2014-03-31 |
$9 |
| 2013-12-31 |
$9 |
| 2013-09-30 |
$1 |
| 2013-06-30 |
$0 |
| 2013-03-31 |
$0 |
| 2012-12-31 |
$1 |
| 2012-09-30 |
$0 |
| 2012-06-30 |
$0 |
| 2012-03-31 |
$0 |
| 2011-12-31 |
$0 |
| 2011-09-30 |
$0 |
| 2011-06-30 |
$1 |
| 2011-03-31 |
|
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.872B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
